REG - Physiomics PLC - Result of AGM

PhysiomicsAnnouncement

18/11/2025 15:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251118:nRSR0446Ia&default-theme=true

RNS Number : 0446I  Physiomics PLC  18 November 2025

18 November 2025

 

Physiomics plc

("Physiomics" or the "Company")

 

Result of AGM

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biometrics company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce that all resolutions
put to shareholders at the Company's annual general meeting, held earlier
today, were duly passed. Voting was conducted by a show of hands and inclusive
of votes received by the Company by way of proxy.

 

Details of the proxy voting results are shown in the table below.

 Ordinary Resolutions                                                       Votes For   %      Votes Against  %      Votes Withheld  Votes Total  % of ISC Voted
 1            Approval of the accounts                                      27,842,565  98.8%  314,631        1.1%   3,461           28,160,657   9.3%
 2            Re-election of Dr Jim Millen as a Director of the Company     26,622,673  94.6%  1,510,182      5.4%   27,802          28,160,657   9.3%
 3            Re-election of Dr Tim Corn as a Director of the Company       26,586,162  94.5%  1,546,693      5.5%   27,802          28,160,657   9.3%
 4            Appointment and renumeration of auditor                       27,774,713  98.6%  375,483        1.3%   10,461          28,160,657   9.3%
 5            Authority to allot shares                                     24,190,035  85.9%  2,007,140      7.1%   1,963,482       28,160,657   9.3%
 Special Resolution
 6            Disapplication of shareholders' statutory pre-emption rights  23,055,357  81.9%  3,141,818      11.2%  1,963,482       28,160,657   9.3%

 

ISC - Issued Share Capital

 

For more information about Physiomics and its services, please visit
www.physiomics.co.uk (http://www.physiomics.co.uk) .

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting-edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 100 commercial projects, with over 140 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGDZMMMKRZGKZM



            Copyright 2019 Regulatory News Service, all rights reserved